These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39565368)

  • 1. Prognostic Value of Baseline Skeletal Muscle Index in Colorectal Cancer Patients Treated with Fruquintinib: A multi-center real world analysis.
    Tang W; Li F; Zheng H; Zhao J; Wei H; Xiong X; Chen H; Zhang C; Xie W; Zhang P; Gong G; Ying M; Guo Q; Wang Q; Fu J
    Int J Colorectal Dis; 2024 Nov; 39(1):186. PubMed ID: 39565368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.
    Zhou Y; Xu Q; Wang J; Leng WB; Cao P; Chen Y; Luo DY; Qiu M; Liu J
    J Evid Based Med; 2024 Sep; 17(3):667-674. PubMed ID: 39327543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Effects of Fruquintinib Combined with Immune Checkpoint Inhibitors on Metastatic Colorectal Cancer.
    Xie MZ; Li YQ; Liang R; Huang SY; Qin SY; Hu BL
    J Gastrointest Cancer; 2024 Dec; 55(4):1620-1627. PubMed ID: 39316296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors.
    Wang Y; Xu J; Dong M; Liu K; Lu Y; Chen K; Cao Y; Shi H; Bei Y; Li J; Zhao J; Cao Y; Lu N; Yang L; Liu H; Cai P; Li K; Yang T; He N; Dong J; Zhang C
    J Gastrointest Oncol; 2024 Aug; 15(4):1519-1533. PubMed ID: 39279967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
    Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
    Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study.
    Yang C; Li B; Dong S; Xu J; Sun X; Liang X; Liu K; Sun K; Yang Y; Ji T; Ye Z; Xie L; Tang X
    Orthop Surg; 2024 Oct; 16(10):2380-2390. PubMed ID: 39030807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
    Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.
    Li J; Wang Z; Zhong H; He Y; Zhang C; Niu Z; Yang S; Zhang T; Zhu L; Shu Y; Gao Y; Peng J; Song Y; Li J; Yuan Y; Zhang H; Yu G; Hua Y; Xiao J; Fu J; Zheng Y; Xue H; Luo X; Shi M; Su W; Qin S
    Oncologist; 2024 Aug; 29(8):e1012-e1019. PubMed ID: 38642091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2024 Aug; 30(15):3100-3104. PubMed ID: 38809262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
    Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
    Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
    Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
    Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
    Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-determined low skeletal muscle index predicts poor prognosis in patients with colorectal cancer.
    Feng Y; Cheng XH; Xu M; Zhao R; Wan QY; Feng WH; Gan HT
    Cancer Med; 2024 Jun; 13(12):e7328. PubMed ID: 38924332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.